McGowanJ. E.,
BamesM. W.,
FinlandM. Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis1975; 132:316–335
MylotteJ. M.,
WhiteD.,
McDermottC.,
HodanC. Nosocomial bloodstream infection at a veterans hospital; 1979 to 1987. Infect Control Hosp Epidemiol1989; 10:455–464
Hibbert-RogersL. C. F.,
HeritageJ.,
Gascoyne-BinziD. M. Molecular epidemiology of ceftazidime resistant Enterobac-teriaceae from patients on a paediatric oncology ward. J Antimicrob Chemother1995; 36:65–82
ShannonK. P.,
PhillipsI. A computer program for the storage and analysis of minimum inhibitory concentrations of antimicrobial agents. Binary1990; 2:89–95
KoontzF. P. Microbial resistance surveillance techniques. Blood cultures versus multiple body site monitoring. Diagn Microbiol Infect Dis1992; 15: Suppl 231S–35S
EmmersonA. M.,
EnstoneJ. E.,
GriffinM.,
KelseyM. C.,
SmythE. T. M. The Second National Prevalence Survey of infection in hospitals - overview of the results. J Hosp Infect1996; 32:175–190
GeerdesH. F.,
ZieglerD.,
LodeH. Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis1992; 15:991–1002
JohnsonA. P.,
SpellerD. C. E.,
GeorgeR. C.,
WarnerM.,
DomingueG.,
EfstratiouA. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ1996; 312:1454–1456
FomsgaardA.,
HoibyN.,
FriisH. M. Prevalence and antibiotic sensitivity to Danish versus other European bacterial isolates from intensive care and hematology/ oncology units. Eur J Clin Microbiol Infect Dis1995; 14:275–281
FassR. J.,
BamishanJ.,
AyersL. W. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother1995; 36:343–353
ComettaA.,
CalandraT.,
BilleJ.,
GlauserM. P.Escherichia coli resistant to fluoroquinolones in patients with cancer neutropenia. N Engl J Med1994; 300:1240–1241
CarratalaJ.,
Fernandez-SevillaA.,
TubauF.,
CallisM.,
GudiolF. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis1995; 20:557–560
KunovaA.,
TruplJ.,
KrcmeryV. Low incidence of quinolone resistance in gram-negative bacteria after five-years use of ofloxacin in prophylaxis during afebrile neutropenia. J Hosp Infect1996; 32:155–156
LiuP. Y. F.,
GurD.,
HallL. M. C.,
LivermoreD. M. Survey of the prevalence of β -lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother1992; 30:429–447
ScaifeW.,
YoungH.-K.,
PatonR. H.,
AmyesS. G. B. Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob Chemother1995; 36:585–586
O’BrienT. F. International Survey of Antibiotic Resistance Group. Resistance to antibiotics at medical centres in different parts of the world. J Antimicrob Chemother1986; 18: Suppl C243–253
WHO Scientific Working Group on monitoring and management of bacterial resistance to antimicrobial agents World Health Organization, Geneva; 1994
Department of Health and PHLS Working Group The prevention and management of Clostridium difficile infection. Heywood, BAPS Health Publications Unit; 1994
Report of the Public Health Laboratory Service Incidence of surgical wound infection in England and Wales. Lancet1960; 2:659–663
SartorC.,
EdwardsJ. R.,
GaynesR. P.,
CulverD. H. National Nosocomial Infections Surveillance System. Evolution of hospital participation in the National Nosocomial Infections Surveillance System 1986 to 1993. Am J Infect Control1995; 23:364–368
National Nosocomial Infections Surveillance (NNIS) System Nosocomial infection rates for interhospital comparison: limitations and possible solution. Infect Control Hosp Epidemiol1991; 12:609–621
PanlilioA. L.,
CulverD. H.,
GaynesR. P. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol1992; 13:582–586
Report of a Combined Working Party of the Hospital Infection Society and the British Society of Antimicrobial Chemotherapy Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect1990; 16:351–377
CoxR. A.,
ConquestC.,
MallaghanC.,
MarplesR. R. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect1995; 29:87–106
WadeJ. J. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - a preliminary report. J Hosp Infect1995; 30: Suppl 483–493
WadeJ. J.,
DesaiN.,
CasewellM. W. Hygienic hand disinfection for the removal of epidemic vancomycin-resistant Enterococcus faecium and gentamicin-resistant Enterobacter cloacae. J Hosp Infect1991; 18:211–218
GautomR. K.,
StewartB.,
CoyleM. B.,
PlordeJ. J.,
SchoenknechtF. D.,
FritscheT. R. Pulsed field gel electrophoretic analysis of vancomycin resistant enterococci (VREs) recovered from Seattle hospitals (Abstract). Am J Clin Pathol1995; 104:223
Hospital Infection Control Practices Advisory Committee (HICPAC) Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol1995; 16:105–113
BrownS.,
AmyesS. G. B.,
ThomsonC. J. Antibiotic resistance in Haemophilus influenzae isolated in England and Wales. 1st European Congress of Chemotherapy. Camforth, Lancs, Parthenon Publishing; 1996 Abstract T135
ScriverS. R.,
WalmsleyS. L.,
KauC. L. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their /J-lactamases. Antimicrob Agents Chemother1994; 38:1678–1680
ShanahanP. M. A.,
ThomsonC. J.,
AmyesS. G. B. Antibiotic susceptibilities of Haemophilus influenzae in central Scotland. Clin Microbiol Infect 1:168–174
ValiL.,
LindsayG.,
ThomsonC. J.,
AmyesS. G. B.β -lactamases in Haemophilus influenzae isolated in Glasgow. 94th Annual Meeting of the ASM Washington, DC: American Society for Microbiology; 1994 Abstract A-72
DaumR. S.,
Murphey-CorbM.,
ShapiraS.,
DippS. Epidemiology of ROB β -lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States. J Infect Dis1988; 157:450–455
BushK.,
JacobyG. A.,
MedeirosA. A. A functional classification scheme for β -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother1995; 39:1211–1233
ValiL.,
ThomsonC. J.,
AmyesS. G. B. Incidence of β -lactam resistance in Haemophilus influenzae. 95th Annual Meeting of the ASM Washington, DC: American Society for Microbiology; 1995 Abstract A-81
RetsemaJ.,
GirardA.,
SchelklyW. Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-memberedring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother1987; 31:1939–1947
RobertsM.,
ComeyA.,
ShawW. V. Molecular characterization of three chloramphenicol acetyltransferases isolated from Haemophilus influenzae. J Bacteriol1982; 151:737–741
BumsJ. L.,
MendelmanP. M.,
LevyJ.,
StullT. L.,
SmithA. L. A permeability barrier as a mechanism of chloramphenicol resistance in Haemophilus influenzae. Antimicrob Agents Chemother1985; 27:46–54
JahnG.,
LaufsR.,
KaulfersP.-M.,
KolendaH. Molecular nature of two Haemophilus influenzae R factors containing resistances and the multiple integration of drug resistance transposons. J Bacteriol1979; 138:584–597
de GrootR.,
ChaffinD. O.,
KuehnM.,
SmithA. L. Trimethoprim resistance in Haemophilus influenzae is due to altered dihydrofolate reductases(s). Biochem J1991; 274:657–662
SteingrubeV. A.,
WallaceR. J.,
BeaulieuD. A membrane-bound precursor β -lactamase in strains of Moraxella catarrhalis and Moraxella nonliquefaciens that produce periplasmic BRO-1 and BRO-2 β -lactamases. J Antimicrob Chemother1993; 31:237–244
SimpsonI. N.,
PlestedS. J. The origin and properties of β - lactamase satellite bands seen in isoelectric focusing. J Antimicrob Chemother1983; 12:127–131
WallaceR. J.,
SteingrubeV. A.,
NashD. R. BRO β -lactamase of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β -lactamase transfer by conjugation in B. catarrhalis M. nonliquefaciens and M. lacunata. Antimicrob Agents Chemother1989; 33:1845–1854
ReichmannP.,
VaronE.,
GuntherE. Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. J Med Microbiol1995; 43:377–385
WeisblumB. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression - a review. J Antimicrob Chemother1985; 16: Suppl A63–90
AszkenasyO. M.,
GeorgeR. C.,
BeggN. T. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Commun Dis Rep CDR Rev1995; 5:R45–R50
WenzelR. P.,
NettlemanM. D.,
JonesR. N.,
PfallerM. A. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med1991; 91: Suppl B221S–227S
FrenchG. L.,
ChengA. F. B.,
LingJ. M. L.,
MoP.,
DonnanS. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect1990; 15:117–125
VincentJ. L.,
BihariP. J.,
SuterP. M. The prevalence of nosocomial infection in intensive care units in Europe - results of the European prevalence of infection in intensive-care (EPIC) study. EPIC International Advisory Committee JAMA1995; 274:639–644
HandwergerS.,
RaucherB.,
AltaracD. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin Infect Dis1993; 16:750–755
CotterillS.,
EvansR.,
FraiseA. P. An unusual source for an outbreak of methicillin-resistant Staphylococcus aureus on an intensive therapy unit. J Hosp Infect1996; 32:207–216
JacobsonK. L.,
CohenS. H.,
InciardiJ. F. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in Group I β -lactamase-producing organisms. Clin Infect Dis1995; 21:1107–1113
BallowC. H.,
SchentagJ. J. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis1992; 15: Suppl 237S–42S
BambergerD. M.,
DahlS. L. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med1992; 152:554–557
LeclercqR.,
DerlotE.,
DuvalJ.,
CourvalinP. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med1988; 319:157–161
Centers for Disease Control and Prevention Nosocomial enterococci resistant to vancomycin - United States 1989-1993. Morb Mort Weekly Rep1993; 42:597–599
HastingsJ. G. M.,
JolleyA. J. Vancomycin resistant and dependent enterococci in a tertiary referral centre. 35th ICAAC San Francisco. Washington, DC: American Society for Microbiology; 1995 Abstract
WoodfordN.,
MorrisonD.,
JohnsonA. P.,
BriantV.,
GeorgeR. C.,
CooksonB. Application of DNA probes for rRNA and Van A genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci. J Clin Microbiol1993; 31:653–658
SaderH. S.,
PfallerM. A.,
TenoverF. C.,
HollisR. J.,
JonesR. N. Evaluation and characterization of multiresistant Enterococcus faecium from 12 US Medical Centers. J Clin Microbiol1994; 32:2840–2842
BatesJ.,
JordensJ. Z.,
GriffithsD. T. Farm animals as a putative reservoir for vancomycin-resistant enterococci infection in man. J Antimicrob Chemother1994; 34:507–516
QuintilianiR.,
EversS.,
CourvalinP. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis1993; 167:1220–1223
EversS.,
ReynoldsP. E.,
CourvalinP. Sequence of the vanB and ddl genes encoding D-alanine: D-lactate and D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene1994; 140:97–102
QuintilianiR.,
CourvalinP. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett1994; 119:359–363
Billot-KleinD.,
GutmannL.,
SableS.,
GuittetE.,
van HeijenoortJ. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant vanB type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol1994; 176:2398–2405
FraimowH. S.,
JungkindD. L.,
LanderD. W.,
DelsoD. R.,
DeanJ. L. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann Intern Med1994; 121:22–26
BiavascoF.,
GiovanettiE.,
MontanariM. R.,
LupidiR.,
VaraldoP. E. Development of in-vitro resistance to glycopeptide antibiotics: assessment of staphylococci of different species. J Antimicrob Chemother1991; 27:71–79
DaumR. S.,
GuptaS.,
SabbaghR.,
MilewskiW. M. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis1992; 166:1066–1072
SanyalD.,
GreenwoodD. An electronmicroscope study of glycopeptide antibiotic-resistant strains of Staphylococcus epidermidis. J Med Microbiol1993; 39:204–210
KaatzG. W.,
SeoS. M.,
DormanN. J.,
LemerS. A. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis1990; 162:103–108
NobleW. C.,
ViraniZ.,
CreeR. G. A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett1992; 72:195–198
WilliamsR. J.,
YangY.-J.,
LivermoreD. M. Mechanisms by which imipenem may overcome resistance in Gram-negative bacilli. J Antimicrob Chemother1986; 18: Suppl E9–13
GehrleinM.,
LeyingH.,
CullmanW.,
WendtS.,
OpferkuchW. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy1991; 37:405–412
Bergogne-BerezinE.,
Joly-GuillouM. L. Antibiotic resistance mechanisms in Acinetobacter. In
TownerK. J.,
Bergogne-BerezinE.,
FewsonC. A.
(eds) The biology of Acinetobacter. taxonomy, clinical importance, molecular biology, physiology, industrial relevance New York: Plenum Press; 199183–115
NordmannP.,
NicolasM. H.,
GutmannL. Penicillin-binding proteins of Rhodococcus equipotential role in resistance to imipenem. Antimicrob Agents Chemother1993; 37:1406–1409
TriasJ.,
NikaidoH. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J Biol Chem1990; 265:15680–15684
LivermoreD. M. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother1992; 36:2046–2048
ZhouX. Y.,
KitzisM.,
GutmanL. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother1993; 37:387–389
ChenH. Y.,
YuanM.,
LivermoreD. M. Mechanisms of resistance to β -lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol1995; 43:300–309
RasmussenB. A.,
YangY.,
JacobusN.,
BushK. Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of β -lactams in three Bacteroides fragilis isolates that harbor a metallo-β -lactamase gene. Antimicrob Agents Chemother1994; 38:2116–2120
BushK.,
JacobyG. A.,
MedeirosA. A. A functional classification scheme for β -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother1995; 39:1211–1233
YangY.,
WuP.,
LivermoreD. M. Biochemical characterization of a β -lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother1990; 34:755–758
NaasT.,
VandelL.,
SoughakoffW.,
LivermoreD. M.,
NordmannP. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing Class A β -lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother1994; 38:1262–1270
NaasT.,
NordmannP. Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci USA1994; 91:7693–7697
SuttonB. J.,
ArtymiukP. J.,
Cordero-BorboaA. E.,
LittleC.,
PhillipsD. C.,
WaleyS. G. An X-ray crystallographic study of the β -lactamase II from Bacillus cereus at 0.35 nm resolution. Biochem J1987; 248:181–188
HawkeyP. M.,
BirkenheadD.,
KerrK. G.,
NewtonK. E.,
HydeW. A. Effect of divalent cations in bacteriological media on the susceptibility of Xanthomonas maltophilia to imipenem, with special reference to zinc ions. J Antimicrob Chemother1993; 31:47–55
ShannonK.,
KingA.,
PhillipsI.β -Lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila. J Antimicrob Chemother1986; 17:45–50
RossoliniG. M.,
ZanchiA.,
ChiesurinA.,
AmicosanteG.,
SattaG.,
GuglielmettiP. Distribution of cphA or related carbapenemase-encoding genes and production of carbapenemase activity in members of the genus Aeromonas. Antimicrob Agents Chemother1995; 39:346–349
WalshT. R.,
PayneD. J.,
MacGowanA. P.,
BennettP. M. A clinical isolate of Aeromonas sobria with three chromosomally mediated inducible β -lactamases: a cephalosporinase, a penicillinase and a third enzyme, displaying carbapenemase activity. J Antimicrob Chemother1995; 35:271–279
HayesM. V.,
ThomsonC. J.,
AmyesS. G. B. Three β -lactamases isolated from Aeromonas salmonicida, including a carbapenemase not detectable by conventional methods. Eur J Clin Microbiol Infect Dis1994; 13:805–811
PatonR.,
MilesR. S.,
AmyesS. G. B. Biochemical properties of inducible β -lactamases produced from Xanthomonas maltophilia. Antimicrob Agents Chemother1994; 38:2143–2149
BaxterI. A.,
LambertP. A. Isolation and partial purification of a carbapenem-hydrolysing metallo-β -lactamase from Pseudomonas cepacia. FEMS Microbiol Lett1994; 122:251–256
ThompsonJ. S.,
MalamyM. H. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β -lactamase II. J Bacteriol1990; 172:2584–2593
PodglajenI.,
BreuilJ.,
CollatzE. Insertion of a novel DNA sequence, IS 1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol1994; 12:105–114
BandohK.,
UenoK.,
WatanabeK.,
KatoN. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study. Clin Infect Dis1993; 16: Suppl 4S382–S386
OsanoE.,
ArakawaY.,
WacharotayankunR. Molecular characterization of an enterobacterial metallo-β -lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother1994; 38:71–78
SendaK.,
ArakawaY.,
ItoH. PCR detection of metallo-β -lactamase producing Pseudomonas aeruginosa resistant to carbapenem. 96th Annual Meeting of ASM New Orleans. Washington, DC: American Society for Microbiology; 1996 Abstract A45, p 141
NandivadaL. S.,
AmyesS. G. B. Plasmid-mediated β -lactam resistance in pathogenic Gram-negative bacteria isolated in South India. J Antimicrob Chemother1990; 26:279–290
ShanahanP. M. A.,
ThomsonC. J.,
AmyesS. G. B.β -Lactam resistance in aerobic faecal flora from general practice patients in the U. K. Eur J Clin Microbiol Infect Dis1994; 13:760–763
HenquellC.,
ChanalC.,
SirotD.,
LabiaR.,
SirotJ. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β -lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother1995; 39:427–430
JelschC.,
LenfantF.,
MassonJ. M.,
SamamaJ. P. Crystallization and preliminary crystallographic data on Escherichia coli TEM-1 β -lactamase. J Mol Biol1992; 223:377–380
Du BoisS. K.,
MarriottM. S.,
AmyesS. G. B. TEM- and SHV-derived extended-spectrum β -lactamases: relationship between selection, structure and function. J Antimicrob Chemother1995; 35:7–22
PayneD. J.,
AmyesS. G. B. Transferable resistance to extended-spectrum β -lactams: a major threat or a minor inconvenience?. J Antimicrob Chemother1991; 27:255–261
SowekJ. A.,
SingerS. B.,
OhringerS. Substitution of lysine at position 104 or 240 of TEM-1 pTZ18R β -lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry1991; 30:3179–3188
HuletskyA.,
KnoxJ. R.,
LevesqueR. C. Role of Ser-238 and Lys-240 in the hydrolysis of 3rd-generation cephalosporins by SHV-type β -lactamases probed by site-directed mutagenesis and 3-dimensional modeling. J Biol Chem1993; 268:3690–3697
VatopoulosA. C.,
PhilipponA.,
TzouvelekisL. S.,
KomninouZ.,
LegakisN. J. Prevalence of a transferable SHV-5 type β - lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J Antimicrob Chemother1990; 26:635–648
BradfordP. A.,
UrbanC.,
JaiswalA. SHV-7, a novel cefotaxime-hydrolyzing β -lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother1995; 39:899–905
Du BoisS. K.,
MarriottM. S.,
AmyesS. G. B. Can clavulanic acid reverse extended-spectrum β -lactamase mutations?. ICAAC, New Orleans Washington, DC: American Society for Microbiology; 1993 582 (Abstract)
PodbielskiA.,
SchonlingJ.,
MelzerB.,
WamatzK.,
LeuschH. G. Molecular characterization of a new plasmid-encoded SHV-type β -lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae. J Gen Microbiol1991; 137:569–578
HenquellC.,
SirotD.,
ChanalC. Frequency of inhibitor- resistant TEM β -lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother1994; 34:707–714
GellertM.,
MisuuchiK.,
O’DeaM. H.,
NashH. A. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA1976; 73:3872–3876
SuginoA.,
PeeblesC. L.,
KruezerK. N.,
CozzarelliN. R. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA1977; 74:4767–4771
VincentS.,
GlaunerB.,
GutmannL. Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition. Antimicrob Agents Chemother1991; 35:1381–1385
CozensR. M.,
MarkiewiczZ.,
TuomanenE. Role of autolysins in the activities of imipenem and CGP 31608, a novel penem, against slowly growing bacteria. Antimicrob Agents Chemother1989; 33:1819–1821
WolfsonJ. S.,
HooperD. C.,
McHughG. L.,
BozzaM. A.,
SwartzM. N. Mutants of Escherichia coli K12 exhibiting reduced killing by both quinolone and /3-lactam antimicrobial agents. Antimicrob Agents Chemother1990; 34:1938–1943
MunshiM. H.,
HaiderK.,
RahamanM. M.,
SackD. A.,
AhmedZ. V.,
MorshedM. G. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type I. Lancet1987; ii:419–421
TanakaM.,
IshiiH.,
SatoK.,
OsadaY.,
NishinoT. Characterization of high level quinolone resistance in Staphylococcus aureus. 31st ICAAC Chicago. Washington, DC: American Society for Microbiology; 1991 Abstract 808, p 233
YoshidaH.,
BogakiM.,
NakamuraS.,
UbukataK.,
KonnoM. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol1990; 172:6942–6949
YoshidaH.,
BogakiH.,
NakamuraM.,
NakamuraS. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother1990; 34:1271–1272
YamagishiJ.,
YoshidaH.,
YamagoshiM.,
NakamuraS. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet1986; 204:367–373
CohenS. P.,
McMurryL. M.,
HooperD. C.,
WolfsonJ. S.,
LevyS. B. Cross-resistance to fluoroquinolones in multiple-antibiotic- resistance (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with changes in addition to OmpF reduction. Antimicrob Agents Chemother1989; 33:1318–1325
OhshitaY.,
HiramatsuK.,
YokotaT. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun1990; 172:1028–1034
KaatzG. W.,
SeoS. M. Up regulation of norA1199 results in fluoroquinolone (FQ) resistance in Staphylococcus aureus (SA). 32nd ICAAC, Anaheim, CA. Washington, DC: American Society for Microbiology; 1992 Abstract 1481, p 357
BlondeauJ.,
YaschukY. Canadian Ciprofloxacin Study Group. Canadian Ciprofloxacin Susceptibility Study: comparative study from 15 medical centers. Antimicrob Agents Chemother1996; 40:1729–1732
TillotsonG.,
HerbertJ. J. F. Comparison of antibiotic susceptibility levels in the United Kingdom. 4th European Congress of Clinical Microbiology and Infectious Diseases; Nice, France: 1989 Abstract 431, p 23
DoemG. V.,
BrueggemannA.,
HolleyH. P.,
RauchA. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother1996; 40:1208–1213
BudnickL. D.,
SchaeflerS. Ciprofloxacin-resistant methicillin- resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group. Am J Public Health1990; 80:810–813
SchabergD. R.,
DillonW. I.,
TerpenningM. S.,
RobinsonK. A.,
BradleyS. F.,
KauffmanC. A. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother1992; 36:2533–2535
ThomsonC. J.,
PatonR. H.,
HoodJ.,
MilesR. S.,
AmyesS. G. B. Antibiotic resistance in urinary bacteria isolated in central Scotland. Int J Antimicrob Agents1992; 1:223–228
MacGowanA. P.,
BrownN. M.,
HoltH. A.,
LoveringA. M.,
McCullochS. Y.,
ReevesD. S. An eight-year survey of the antimicrobial susceptibility patterns of 85,971 bacteria isolated from patients in a district general hospital and the local community. J Antimicrob Chemother1993; 31:543–557
AmyesS. G. B.,
BairdD. R.,
CrookD. W. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother1994; 34:639–648
BrownJ. C.,
ShanahanP. M. A.,
Jesudason My ThomsonC. J.,
AmyesS. G. B. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother1996; 37:891–900
GillespieS. H.,
FoxR.,
PatelS.,
NgowiF.,
TillotsonG. S. Antibiotic susceptibility of Enterobacteriaceae isolated from patients in Northern Tanzania. J Antimicrob Chemother1992; 29:227–229
CoronadoV. R.,
EdwardsJ. R.,
CulverD. H.,
GaynesR. P. and the National Nosocomial Infections Surveillance (NNIS) System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol1995; 16:71–75
ReinaJ.,
BorrellN.,
SerraA. Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987-1991. Eur J Clin Microbiol Infect Dis1992; 11:1163–1166
ChildJ.,
AndrewsJ.,
BoswellF.,
BrenwaldN.,
WiseR. The in- vitro activity of CP99, 219, a new naphthylpyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother1995; 35:869–876
MarcoF.,
JonesR. N.,
HobanD. J.,
PignatariA. C.,
YamaneN.,
FreiR. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother1994; 33:647–654
HoshinoK.,
KutamuraA.,
MorrisseyI.,
SatoK.,
KatoJ.-I.,
IkedaF. I. Comparison of inhibition of Escherichia coli topoisome- rase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother1994; 38:2623–2627
DaviesJ.,
FloukC.,
YagisawaM.,
WhiteT. J. Occurrence and function of aminoglycoside-modifying enzymes. In
SebekO. K.,
LaskinA. J.
(eds) Genetics of industrial microorganisms Washington, DC: American Society for Microbiology; 1979166–169
Committee on Human Health Risk Assessment of Using Subtherapeutic Antibiotics in Animal Feeds Human health risks with the subtherapeutic use of penicillin or tetracyclines in animal feed. Washington, DC: National Academy Press; 1989
Perez-TralleroE.,
ZigorragaC. Resistance to antimicrobial agents as a public health problem: importance of the use of antibiotics in animals. Int J Antimicrob Agents1995; 6:59–63
DonnellyJ. P.,
VossA.,
WitteW.,
MurrayB. E. Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?. J Antimicrob Chemother1996; 37:389–390
Trieu-CuotP.,
CourvalinP. Evolution and transfer of aminoglycoside resistance genes under natural conditions. J Antimicrob Chemother1986; 18: Suppl C93–102
EndtzH. P.,
RuijsG. J.,
Van KlingerenB.,
JansenW. H.,
van der ReydenT.,
MoutonR. P. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother1991; 27:199–208
JacobsonK. L.,
CohenS. H.,
InciardiJ. F. The relationship between antecedent antibiotic use and resistance to extended- spectrum cephalosporins in group I β -lactamase-producing organisms. Clin Infect Dis1995; 21:1107–1113
CourcolR. J.,
PinkasM.,
MartinG. R. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother1989; 23:441–451
NissinenA.,
GronroosP.,
HuovinenP. Development of /3- lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis1995; 21:1193–1196